City

Columbus (1)

Paris (1)

Phoenix (1)

Stanford (1)

Condition

Nasal Surgical Procedures (3)

Dental Anesthesia (1)

Intranasal Drug Administration (1)

NASAL SURGICAL PROCEDURES (1)

Nasal Obstruction (1)

RHINOPLASTY (1)

Regenerative Medicine (1)

Overall Status

Completed (1)

Enrolling by invitation (1)

Recruiting (1)

Withdrawn (1)

Phase

n/a (1)

phase 2 (1)

phase 3 (1)

Sponsor

Groupe Hospitalier Paris Saint Joseph (1)

Mayo Clinic (1)

Richard Cartabuke (1)

Stanford University (1)

Collaborator

Duke University (1)

Harvard University (1)

Loma Linda University (1)

University of Cincinnati (1)

University of Kansas Medical Center (1)

University of Washington (1)

Vanderbilt University School of Medicine (1)

Washington University School of Medicine (1)

Intervention

3d nasal reconstruction planning (1)

intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days (1)

intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg. (1)

no intervention (1)

oxymetazoline (1)

Study Documents

Intervention Type

drug (2)

other (1)

procedure (1)

Funder Type

Other (4)

Study Type

Interventional (3)

Observational (1)

nasal surgical procedures

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Nasal Obstruction, Nasal Surgical Procedures Trial in Stanford (Intra-operative single intravenous(iv) dose of "cephalexin" 2 g

Enrolling by invitation

Nasal Obstruction
Nasal Surgical Procedures

Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg.
Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days